The Effectiveness of PET-Scan in Diagnosis and Treatment of Non-Small Cell Lung Carcinoma (NSCLC) and Lymphoma: A Comprehensive Review of Literature

Document Type : Review Article

Authors

1 Assistant Professor, Department of Health Service Management, School of Management and Medical Information Services, Tehran University of Medical Sciences, Tehran, Iran

2 Assistant Professor, Department of Health Management and Economics, School of Public Health, And Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran

3 Medical Lecturer, Medical College, Shantou University, China

4 Health Technology Assessment (HTA) Office, Deputy of Curative Affairs, Ministry of Health and Medical Education, Tehran, Iran

Abstract

Background: Positron emission tomography (PET) scan is a non-invasive, complicated and expensive medical imaging technology used for diagnosis and treatment of various diseases including cancers. This study aimed to evaluate the safety and effectiveness of this technology.Methods: The major medical electronic databases including Cochrane Library, Google Scholar, MEDLINE and IranMedex were searched. The studies that compared PET-scan with other diagnostic methods in terms of sensitivity, specificity and safety were considered in this review.Findings: PET-scan has been found to be a non-invasive and safe procedure for diagnosing metastatic NSCLC with a sensitivity and specificity of 74-95% and 81-97%, respectively. On the other hand, the sensitivity and specificity of computed tomography (CT) scan have been reported as 60-67% and 73-77%, respectively. The corresponding values for mediastinoscopy have been 78% and 100%. In lymphoma, the specificity and sensitivity of PET-scan (90% and 79-100%, respectively) have been higher than those of gamma scan. Although PET-scan is not an appropriate method for screening and diagnosis of cancer, it can contribute to staging and follow-up processes in cases of NSCLC and lymphoma. This technology adds 0.046 years (about 17 days) to the patient's life. Conclusion: PET-scan is a safe technology that has better diagnostic performance in comparison with similar technologies. The application of this method in staging and follow-up of NSCLC and lymphoma can prevent unnecessary surgeries and add a few years to the lives of patients.

Keywords

References

  1. Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care 2007; 23(1): 30-5.
  2. Department of Health. A framework for the development of Positron Emission Tomography (PET) services in England [Online] 2005. Available from: URL:
  3. http://webarchive.nationalarchives.gov.uk/+/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4121030.pdf.
  4. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 2007; 11(44): iii-267.
  5. Abbasidezfuli A, Adhami Sh, Javaherzadeh M, Daneshvar A, Pejhan S, Arab M, et al. Role of operation in lung cancer. Journal of Kordestan University of Medical Sciences 2004; 8(3): 59-67. [In Persian].
  6. Medicare Services Advisory Committee. Positron Emission Tomography. Part 2(ii). Canberra: Medicare Services Advisory Committee; 2001.
  7. American Cancer Society .Lung Cancer (Non-Small Cell) [Online] 2007. [cited 2007 Oct 31]; Available from: URL: http://www.cancer.org/
  8. Cleemput I, Dargent G, Poelmans J, Camberlin C, Van Del Burel A, Ramaekers D. HTA Tomographie par Emission de Positrons en Belgique. KCE Reports; 2005. p. 22
  9. Laupacis A. Health Technology Assessment of PET. Toronto: Institute for Clinical Evaluative Sciences (ICES); 2001.
  10. Danish Centre for Evaluation and Health Technology Assessment. Positron Emission Tomography (PET) with 18-F-Fluorodeoxyglucose (FDG). A Literature Review of Evidence for Clinical use in the Fields of Oncology, Cardiology and Neurology. Copenhagen: DACEHTA; 2001.
  11. Bourguet P, Bosquet L, Corone C, Devillers A, Foehrenbach H, Lumbroso JD, et al. Recommendations for clinical practice: Standards, Options and Recommendations for utilization of positron emission tomography with [18F]-FDG (FDG-PET) in oncology (full report). Paris: FNCLCC,Recommendations for clinical practice. [Online] 2003. Available from URL: http://www.fnclcc.fr/, 2003.
  12. HTBS-HTA (Health Technology Board for Scotland). Positron Emission Tomography (PET) Imaging in Cancer Management. Glasgow: Health Technology Board for Scotland (HTBS) (merged into NHS Quality Improvement Scotland (NHS QIS); 2002.
  13. AETMIS. Positron emission tomography in Quebec. Montreal [Online] 2003. Available from URL: http://www.aetmis.gouv.qc.ca, 2003.
  14. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004; 45(1): 85-92.
  15. Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14(1): 123-30.
  16. Dobert N, Menzel C, Berner U, Hamscho N, Wordehoff N, Mitrou P, et al. Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes. Cancer Biother Radiopharm 2003; 18(4): 565-71.
  17. Itti E, Haioun C, Rahmouni A, Reyes F, Meignan M. Agressive large cell lymphoma: early assessment of therapeutic efficacy by positron emission tomography. Medecine Nucleaire 2004; 28(7): 327-32.
  18. Zinzani PL, Chierichetti F, Zompatori M, Tani M, Stefoni V, Garraffa G, et al. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 2002; 43(6): 1239-43.
  19. Hicks RJ, Binns DS, Fawcett ME, Ware RE, Kalff V, McKenzie AF, et al. Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. Med J Aust 1999; 171(10): 529-32.
  20. NHS Quality Improvement Scotland. HTA Report 2: Positron emission tomography (PET) imaging in cancer management; Understanding HTBS Advice; Use of PET imaging for cancer in Scotland. Amendment to full report published July 2005. Glasgow: National Institue for Health Research; 2005.
Journal of Isfahan Medical School
Volume 29, Issue 167 - Serial Number 167
November and December 2012
Pages 2447-2456

Files

History

  • Receive Date: 15 August 2011
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics